Sodium Bicarbonate in Intra-dialytic Hypertension in Chronic Hemodialysis Patients
NCT ID: NCT07231900
Last Updated: 2025-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2/PHASE3
40 participants
INTERVENTIONAL
2025-11-10
2027-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bicarbonate Administration in CKD
NCT02915601
Effects of Oral Sodium Bicarbonate Supplementation in Haemodialysis Patients (BicHD)
NCT02692378
The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity
NCT02896309
Bicarbonate Administration and Cognitive Function in Midlife and Older Adults With CKD
NCT04600323
Effect of Varied Dialysate Bicarbonate Levels on Phosphate and Potassium Removal
NCT01930370
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sodium bicarbonate
PO Sodium bicarbonate 500mg X2/day
Sodium Bicarbonate (NaHCO3)
Prescribing Sodium Bicaronate for intra-dualytic hypertension
Placebo
1 tab X2/day
Placebo
1 tab X 2/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sodium Bicarbonate (NaHCO3)
Prescribing Sodium Bicaronate for intra-dualytic hypertension
Placebo
1 tab X 2/day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 3 dialysis per week, KTV\>1.2
* capable of informed concent.
* rise in blood pressure during hemodialysis \> 10 mm Hg, for at least 50% of dialysis sessions in the month prior to inclusion.
* Normal volume status, by clinical physician assessment + bioimpedance
Exclusion Criteria
* pregnancy
* unable to sign informed concent
* planned for kidney transplant in the following 3 month.
* congestive heart failure (NYHA 3-4)
* hospitalization for acute MI or CHF in the past 3 months.
* low compliece to medical therapy
* regular pre-dialysis tests with bicarbonate \> 24 in the past 3 months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assaf-Harofeh Medical Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shani Zilberman Itskovich
Dr.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shamir medical center
Ẕerifin, Is, Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0208-25-ASF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.